Foundation Medicine, Inc. (NASDAQ:FMI) CFO Jason Ryan sold 6,683 shares of the firm’s stock in a transaction on Thursday, July 6th. The stock was sold at an average price of $38.84, for a total value of $259,567.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jason Ryan also recently made the following trade(s):

  • On Friday, June 2nd, Jason Ryan sold 5,573 shares of Foundation Medicine stock. The stock was sold at an average price of $40.00, for a total value of $222,920.00.
  • On Tuesday, April 18th, Jason Ryan sold 503 shares of Foundation Medicine stock. The stock was sold at an average price of $34.55, for a total value of $17,378.65.

Foundation Medicine, Inc. (NASDAQ:FMI) traded up 1.99% during trading on Friday, reaching $38.35. The company had a trading volume of 155,078 shares. Foundation Medicine, Inc. has a 52 week low of $17.10 and a 52 week high of $43.15. The firm’s market capitalization is $1.37 billion. The stock has a 50 day moving average price of $39.19 and a 200 day moving average price of $29.62.

Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.02) by $0.29. Foundation Medicine had a negative net margin of 126.17% and a negative return on equity of 80.75%. The business had revenue of $26.32 million during the quarter, compared to analysts’ expectations of $29.07 million. During the same period in the previous year, the company posted ($0.50) earnings per share. Foundation Medicine’s revenue for the quarter was down 13.3% compared to the same quarter last year. Analysts predict that Foundation Medicine, Inc. will post ($4.34) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Foundation Medicine, Inc. (FMI) CFO Jason Ryan Sells 6,683 Shares” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/07/07/foundation-medicine-inc-fmi-cfo-jason-ryan-sells-6683-shares.html.

A number of large investors have recently bought and sold shares of FMI. Pioneer Investment Management Inc. acquired a new stake in Foundation Medicine during the first quarter valued at approximately $10,502,000. Bank of New York Mellon Corp raised its stake in Foundation Medicine by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 60,762 shares of the company’s stock valued at $1,959,000 after buying an additional 2,232 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new stake in Foundation Medicine during the first quarter valued at approximately $218,000. Wells Fargo & Company MN raised its stake in Foundation Medicine by 7.0% in the first quarter. Wells Fargo & Company MN now owns 10,579 shares of the company’s stock valued at $341,000 after buying an additional 692 shares during the last quarter. Finally, Whittier Trust Co. raised its stake in Foundation Medicine by 4.8% in the first quarter. Whittier Trust Co. now owns 42,053 shares of the company’s stock valued at $1,356,000 after buying an additional 1,914 shares during the last quarter. 31.50% of the stock is currently owned by institutional investors.

A number of equities analysts have recently issued reports on the company. BidaskClub downgraded Foundation Medicine from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. ValuEngine upgraded Foundation Medicine from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded Foundation Medicine from a “sell” rating to a “hold” rating in a research report on Thursday, April 6th. BTIG Research upgraded Foundation Medicine from a “neutral” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Monday, May 15th. Finally, William Blair reiterated a “buy” rating on shares of Foundation Medicine in a research report on Monday, April 3rd. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Foundation Medicine presently has an average rating of “Hold” and an average price target of $30.25.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.